Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of ganaxolone oral suspension in Chinese patients aged 2 years and older with CDKL5 deficiency disorder and seizures
CTR20250141Phase 4Active
- Sponsor
- Marinus Pharmaceuticals
- Start
- Apr 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ganaxolone in CDKL5 deficiency disorder (CDD), sponsored by Marinus Pharmaceuticals. Started Apr 2025; status: active.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on CTR20250141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250141.